Form 8-K - Current report:
SEC Accession No. 0001493152-26-007587
Filing Date
2026-02-20
Accepted
2026-02-20 16:00:33
Documents
14
Period of Report
2026-02-18
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 47181
2 EX-99.1 ex99-1.htm EX-99.1 20746
  Complete submission text file 0001493152-26-007587.txt   294439

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE bctx-20260218.xsd EX-101.SCH 4233
4 XBRL DEFINITION FILE bctx-20260218_def.xml EX-101.DEF 27466
5 XBRL LABEL FILE bctx-20260218_lab.xml EX-101.LAB 38023
6 XBRL PRESENTATION FILE bctx-20260218_pre.xml EX-101.PRE 26082
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 7537
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 8-K | Act: 34 | File No.: 001-40101 | Film No.: 26659690
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)